Lutathera Dose Modification for Adverse Reactions

FDA Prescribing Information, Table 2 (revised 2024)

Determines whether lutetium Lu-177 dotatate (Lutathera) should be continued at full activity, withheld and resumed at 3.7 GBq, or permanently discontinued, based on the type and severity of an adverse reaction.

Also searched as: lutetium-177 · dotatate · PRRT · theranostics · GEP-NET · lutetium · neuroendocrine

Hepatotoxicity

Hypersensitivity reaction (CTCAE grade)

G1 allergic reaction without systemic intervention; G2 oral intervention indicated; G3 bronchospasm/hospitalization/IV intervention; G4 life-threatening.

Anemia (hemoglobin)

Neutropenia, afebrile (ANC)

Febrile neutropenia

Thrombocytopenia (platelets)

Renal toxicity

Creatinine clearance estimated by Cockcroft-Gault using actual body weight.

Information

Incomplete input

Please provide: at least one adverse-reaction category.

How this tool works

Lutathera is given as 7.4 GBq (200 mCi) every 8 weeks for 4 doses in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The prescribing information defines explicit dose-modification rules for renal toxicity, hepatotoxicity, myelosuppression (thrombocytopenia managed from grade 2; anemia and neutropenia from grade 3), and hypersensitivity. Answer any applicable categories; the tool reports the most conservative applicable action.

References

Implemented from the cited published sources. Educational use only; confirm against current guidelines before clinical use.

Related calculators

Same subspecialty, overlapping subject matter.

Pluvicto Dose Modification for Adverse Reactions